CD19 and lymphoma: Unlike CAR T-cell therapy, which specifically targets the CD19 antigen on lymphoma cells, alloSCT offers a strong immune response against multiple unknown tumor antigens through the graft-versus-lymphoma effect that is exerted by the donor stem cells [48,49].